Recent

% | $
Quotes you view appear here for quick access.

Microsoft Corporation Message Board

lws2000 242 posts  |  Last Activity: 14 hours ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • 1.Greece debt crisis: Eurozone summit strikes deal--BBC, 7-13-15
    2. Iran nuclear talks: Deal 'near completion'----BBC, 7-13-15

  • Reply to

    Breakthrough Therap

    by tantamount_to_a_cure Jul 11, 2015 4:58 PM
    lws2000 lws2000 Jul 11, 2015 9:08 PM Flag

    Breakthrough for Novartis (heart); JNJ/Janssen next (Cancer): Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. As a result, it is expected to be one of the biggest new drug launches of 2015.

  • lws2000 lws2000 Jul 11, 2015 9:15 AM Flag

    From Irish----"Registry studies allow all patients with the disease (e.g. MF) access to the drug before full market approval and after Phase II. Registry studies are non-clinical studies that make the drug available worldwide with reporting on efficacy in a study that acts as a de facto Phase III without delaying/denying all patient access to the drug. ODD status is the special status and mechanism for this to occur. Registry studies could be why Janssen predicts rapid pace to market and has opened so many trial sites. Registry studies are also mentioned publicly by Geron during partnership with Janssen. I think registry studies as a path forward is an overlooked and important option and piece of puzzle that could bring Imetelstat to all MF patients very quickly and before any Phase III. Imetelstat meets 2/3 ODD criteria to distribute drug to all MF patients as part of registry study prior to full market approval. The final criteria will be BAT status. Best available therapy will be proven beyond CR in a patient population refractory to JAK. "--Thank you

    These are very important concepts:
    1. Registry Studies as a logical follow-on to ODD (de facto Phase III)
    2. Benefits to those who were on JAK (comparing IMET to JAK)
    3. BAT (Best Available Therapy) for the blood cancer cousins, internationally

  • There is no question that JNJ/Janssen would not be opening so many trials around the world unless they were absolutely sure of the results (within statistical limits). Since they are going into these trials (39 at last count) with the full knowledge of Mayo Clinics successes (remissions, improvements, stabilization), the probability of their continuing success is very, very high. JNJ is going for universal approval for IMET from the FDA and similar agencies worldwide. The uses for IMET in most cancers and beyond (aging for example) are many and varied. The blood cancer cousins are first in line. The FDA has already granted Janssen Orphan-Drug-Designation (ODD).

    This is the order that JNJ/Janssen will bring telomere modification into the lives of cancer patients (and perhaps others), but there will be considerable overlap. Imetelstat is already a success with Orphan-Drug-Status already in its procession. The 39 international sites will reinforce Mayo Clinics original progress, which brings remission to some, and benefits to most (80% in MF).

    The Order of Things (decades of research):
    1. MF
    2. MDS
    3. AML
    4. Combination Drugs
    5. Telomeres in general, including cancer stem cells, solid tumors, and aging

  • lws2000 lws2000 Jul 10, 2015 6:15 PM Flag

    At least you agree about the medical "successes". Some on this board still seem to believe that there are significant problems with IMET (probably short bashers like Maine and his group). Dr.S took IMET to Mayo Clinic, Dr. T and JNJ/Janssen. That is a "good days work". In my mind: New Geron=JNJ Jr., which controls the PPS. Dr. S will do what ever JNJ tells him to do. I believe that the medical successes will dominate.

  • lws2000 lws2000 Jul 10, 2015 1:58 PM Flag

    There is no question that JNJ would not be opening so many trials around the world unless they were absolutely sure of the results (within statistical limits). Since they are going into these trials (39 at last count) with the full knowledge of Mayo Clinics successes (remissions, improvements, stabilization), the probability of their continuing success is very, very high. JNJ is going for universal approval for IMET from the FDA and similar agencies worldwide. The uses for IMET in most cancers and beyond (aging for example) are many and varied. The blood cancer cousins are first in line.

  • lws2000 lws2000 Jul 9, 2015 6:07 PM Flag

    At the moment it appears that many investors are waiting for absolute confirmation that IMET is all that Mayo Clinic claims that it is (Tantamount to a Cure). When JNJ/Janssen reveals all, the entry price will be much higher. IMET is already a medical success and Orphan-Drug-Status gives Janssen, the sponsor, wide latitude in its use.

  • This is the likely order that JNJ/Janssen will bring telomere modification into the lives of cancer patients (and perhaps others), but there will be considerable overlap. Imetelstat is already a success with Orphan-Drug-Status already in its procession. The 39 international sites will reinforce Mayo Clinics original progress, which brings remission to some, and benefits to most (80% in MF).

    The Order of Things (decades of research):
    1. MF
    2. MDS
    3. AML
    4. Combination Drugs
    5. Telomeres in general, including cancer stem cells, solid tumors, and aging

  • Reply to

    Thoughts on a buyout

    by sdrawkcabeman Jun 25, 2015 2:40 PM
    lws2000 lws2000 Jul 9, 2015 10:36 AM Flag

    JNJ, with, IMET, is going after: 1. Blood Cancer Cousins (MF, MDS, AML); 2. Combination medicines; 3. Cancer Stem Cells; 4. Solid Cancers; 5. Studying Telomeres, the Aging Process and Immortal Cells. These trials and studies will overlap. Geron, as a partner of JNJ/Janssen, and also listed separately, will be a major beneficiary. These coming weeks will be very important and interesting.

  • Reply to

    Tập đoàn y tế Geron Message Board

    by shantilouise Jul 8, 2015 11:27 AM
    lws2000 lws2000 Jul 8, 2015 3:18 PM Flag

    I meant "Vietnamese".

  • Reply to

    Tập đoàn y tế Geron Message Board

    by shantilouise Jul 8, 2015 11:27 AM
    lws2000 lws2000 Jul 8, 2015 3:05 PM Flag

    Medical Geron Corporation Message Board. The language is Viennese. We have been "hacked".

  • Reply to

    Thoughts on the litigation

    by rattllebug Jul 7, 2015 5:36 PM
    lws2000 lws2000 Jul 7, 2015 5:44 PM Flag

    Clearly this was a "frivolous-litigation" that tried to take advantage of Geron, when they thought they had an upper hand, and Geron was disadvantaged. Geron did nothing wrong, as you have shown. If anything, Geron should be owed some compensation.

  • Reply to

    JNJ/Janssen and the IMET Continuing Saga

    by comsensea Jul 3, 2015 6:56 PM
    lws2000 lws2000 Jul 7, 2015 3:55 PM Flag

    You are correct. These "breakthroughs" do not have to happen in any particular order, and, with the 3 blood cancer cousins, they are already overlapping. This is all about telomeres, and their importance in medical research. MF was first out of the box.

  • Reply to

    JNJ/Janssen and the IMET Continuing Saga

    by comsensea Jul 3, 2015 6:56 PM
    lws2000 lws2000 Jul 7, 2015 7:53 AM Flag

    JNJ/Janssen and Mayo Clinic are reliable sources of information about patients progress and medical science. Listen to them at conferences and in the journals. The next 24 weeks (time for a new MF trial) at 39 sites will be the key to IMET's future.

  • Reply to

    JNJ/Janssen and the IMET Continuing Saga

    by comsensea Jul 3, 2015 6:56 PM
    lws2000 lws2000 Jul 5, 2015 10:15 AM Flag

    The Order of Things (decades of research):
    1. MF
    2. MDS
    3. AML
    4. Combination Drugs
    5. Telomeres in general, including cancer stem cells, solid tumors, and aging

  • Reply to

    JNJ/Janssen and the IMET Continuing Saga

    by comsensea Jul 3, 2015 6:56 PM
    lws2000 lws2000 Jul 4, 2015 7:51 AM Flag

    JNJ/Janssen already believes that they know many of the answers, based upon the Mayo Clinic successful trials and studies. They are going international with IMET, as one of the "core" drugs in treating blood cancers, that brings remissions and hope of a cure. No other medicine can do that. It does look like a "UN roster".

  • Reply to

    I'm out, clincial trial delay last straw

    by shortakilla Jul 2, 2015 6:06 PM
    lws2000 lws2000 Jul 3, 2015 8:57 AM Flag

    Forget about the "Old-Geron" and concentrate on the "New Geron=JNJ Jr.". JNJ is in control and making all decisions, but Geron is still listed as a public company. JNJ obviously has their reasons for not absorbing Geron, which could happen at anytime. JNJ has been purposely silent about that. The fact that the trials are "delayed" is of no importance. In my view, the fact that 39 sites have been announced means that the trials are underway.

  • Reply to

    Show 39 Study Locations

    by pedmac2000 Jul 2, 2015 12:08 PM
    lws2000 lws2000 Jul 2, 2015 1:04 PM Flag

    This will be one of the largest and most important sets of international trials in the history of medicine, JNJ would not allow this much exposure unless they were fully confident in the "staying-power" of IMET.

  • Reply to

    Computers Taking Short Term Profits

    by lws2000 Jul 1, 2015 2:14 PM
    lws2000 lws2000 Jul 1, 2015 11:56 PM Flag

    There was profit taking, and there was certainly more than one reason. I think the upward tend will hold and accelerate for the reasons previously stated (safety, need, uniqueness, ODD, 36 new trials).

  • Reply to

    Computers Taking Short Term Profits

    by lws2000 Jul 1, 2015 2:14 PM
    lws2000 lws2000 Jul 1, 2015 6:59 PM Flag

    The log/short-hedge-funds operate in channels (set by the computers) that determine the buy and sell points. This can be very successful, and Geron traders have mastered the game. If the volume gets too big, and the news gets too good, the computer programs cannot function efficiently and get overwhelmed. This seems to be happening, with out-of-channel closings trending higher.

MSFT
46.81+0.11(+0.24%)Aug 3 4:00 PMEDT